StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Validoxylamine A

HCID 178951086
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
82309-75-9
Standard-SMILES
OCC1=C[C@H](N[C@H]2C[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
InChIKey
YCJYNBLLJHFIIW-MBABXGOBSA-N
Summenformel
C14H25NO8
Durchschnittliche Molmasse
335,35 g/mol

Überblick

Validoxylamine A is an amino cyclitol that is (1R,2S,3S,4S,6R)-4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol in which one of the hydrogens attached to the nitrogen is replaced by a (1R,4R,5R,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl group. It has a role as an antibiotic insecticide, an animal metabolite, a bacterial metabolite and an EC 3.2.1.28 (alpha,alpha-trehalase) inhibitor. It is a secondary amino compound and an amino cyclitol. It is functionally related to a validamine. It is a conjugate base of a validoxylamine A(1+).

Namen und Bezeichner

Bevorzugter Name
Validoxylamine A
IUPAC
(1S,2S,3R,6S)-4-(hydroxymethyl)-6-[[(1S,2S,3S,4R,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl]amino]cyclohex-4-ene-1,2,3-triol
Englischer Name
Validoxylamine a
Summenformel
C14H25NO8
Molmasse
335.35

Namen und Synonyme

Validoxylamine A38665-10-0(+)-Validoxylamine ACHEBI:131941(1S,2S,3R,6S)-4-(hydroxymethyl)-6-[[(1S,2S,3S,4R,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl]amino]cyclohex-4-ene-1,2,3-triol(1s,2s,3r,6s)-4-(Hydroxymethyl)-6-{[(1s,2s,3s,4r,5r)-2,3,4-Trihydroxy-5-(Hydroxymethyl)cyclohexyl]amino}cyclohex-4-Ene-1,2,3-Triol(1S,2S,3R,6S)-4-(hydroxymethyl)-6-(((1S,2S,3S,4R,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl)amino)cyclohex-4-ene-1,2,3-triolRefChem:1935741,5,6-Trideoxy-5-(hydroxymethyl)-1-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-D-chiro-inositol; (+)-Validoxylamine A;VALIDOXYLAMINECHEMBL1236649SCHEMBL29375116
Weitere Namen anzeigen
chiro-Inositol, 1,5,6-trideoxy-5-(hydroxymethyl)-1-[[4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-, stereoisomerchiro-Inositol, 1,5,6-trideoxy-5-(hydroxymethyl)-1-[[4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-, stereoisomer (9CI)
AV182793C17700Q27225311D-chiro-Inositol, 1,5,6-trideoxy-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-, (1S-(1alpha,4alpha,5beta,6alpha))-D-chiro-Inositol, 5-(hydroxymethyl)-1,5,6-trideoxy-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-, (1S-(1-alpha,4-alpha,5-beta,6-alpha))-

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
-4,1
Polarare Oberfläche (TPSA)
174 Ų
H-Brücken-Donoren
9
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
4
Schwere Atome
23
Formalladung
0
Komplexität
433

Physikochemische Eigenschaften

Siedepunkt
602.6 · 602.6±55.0 °C(Predicted)
Dichte
1.61 · 1.61±0.1 g/cm3(Predicted)
pka
13.49 · 13.49±0.70(Predicted)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Sicherheit und Schutzausrüstung

Minimum Risk LevelIntermediate Oral: 0.3 mg/kg/day (L134) Chronic Oral: 0.3 mg/kg/day (L134)

Toxikologische Informationen

TreatmentZinc poisoning is treated symptomatically, often by administering fluids such as water or milk, or with gastric lavage. (L49)
Health EffectsChronic exposure to zinc causes anemia, atazia, lethargy, and decreases the level of good cholesterol in the body. It is also believed to cause pancreatic and reproductive damage. (L49)
Exposure RoutesOral (L49) ; inhalation (L49) ; dermal (L49)
Toxicity Summary · 1 Eintrag

Anaemia results from the excessive absorption of zinc suppressing copper and iron absorption, most likely through competitive binding of intestinal mucosal cells. Unbalanced levels of copper and zinc binding to Cu,Zn-superoxide dismutase has been linked to amyotrophic lateral sclerosis (ALS). Stomach acid dissolves metallic zinc to give corrosive zinc chloride, which can cause damage to the stomach lining. Metal fume fever is thought to be an immune response to inhaled zinc. (L48, L49, A49)

Signs and Symptoms · 1 Eintrag

Ingestion of large doses of zinc causes stomach cramps, nausea, and vomiting. Acute inhalation of large amounts of zinc causes metal fume fever, which is characterized by chills, fever, headache, weakness, dryness of the nose and throat, chest pain, and coughing. Dermal contact with zinc results in skin irritation. (L49)

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Zinc can enter the body through the lungs, skin, and gastrointestinal tract. Intestinal absorption of zinc is controlled by zinc carrier protein CRIP. Zinc also binds to metallothioneins, which help prevent absorption of excess zinc. Zinc is widely distributed and found in all tissues and tissues fluids, concentrating in the liver, gastrointestinal tract, kidney, skin, lung, brain, heart, and pancreas. In the bloodstream zinc is found bound to carbonic anhydrase in erythrocytes, as well as bound to albumin, _2-macroglobulin, and amino acids in the the plasma. Albumin and amino acid bound zinc can diffuse across tissue membranes. Zinc is excreted in the urine and faeces. (L49)

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
82309-75-9
ChEMBL
CHEMBL1236649
ChEBI
CHEBI:131941
Nikkaji
J19.184A